nodes	percent_of_prediction	percent_of_DWPC	metapath
Flecainide—CYP2D6—Codeine and Morphine Metabolism—UGT2B7—urinary bladder cancer	0.005	0.0837	CbGpPWpGaD
Flecainide—CYP2D6—Miscellaneous substrates—CYP4B1—urinary bladder cancer	0.00325	0.0545	CbGpPWpGaD
Flecainide—CYP2D6—Fatty acids—CYP4B1—urinary bladder cancer	0.00272	0.0456	CbGpPWpGaD
Flecainide—SCN4A—L1CAM interactions—CNTN2—urinary bladder cancer	0.00256	0.0429	CbGpPWpGaD
Flecainide—CYP2D6—Tamoxifen metabolism—UGT2B7—urinary bladder cancer	0.00231	0.0387	CbGpPWpGaD
Flecainide—CYP2C9—Tamoxifen metabolism—UGT2B7—urinary bladder cancer	0.00229	0.0384	CbGpPWpGaD
Flecainide—CYP2D6—Oxidation by Cytochrome P450—POR—urinary bladder cancer	0.00187	0.0314	CbGpPWpGaD
Flecainide—CYP2C9—Oxidation by Cytochrome P450—POR—urinary bladder cancer	0.00186	0.0311	CbGpPWpGaD
Flecainide—CYP2C9—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—urinary bladder cancer	0.00177	0.0297	CbGpPWpGaD
Flecainide—SCN5A—L1CAM interactions—CNTN2—urinary bladder cancer	0.00174	0.0291	CbGpPWpGaD
Flecainide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP4B1—urinary bladder cancer	0.0014	0.0235	CbGpPWpGaD
Flecainide—CYP2C9—Arachidonic acid metabolism—CYP4B1—urinary bladder cancer	0.00103	0.0173	CbGpPWpGaD
Flecainide—SCN4A—Axon guidance—CNTN2—urinary bladder cancer	0.000969	0.0162	CbGpPWpGaD
Flecainide—Photosensitivity reaction—Epirubicin—urinary bladder cancer	0.000928	0.000987	CcSEcCtD
Flecainide—Feeling abnormal—Cisplatin—urinary bladder cancer	0.000928	0.000987	CcSEcCtD
Flecainide—Paraesthesia—Etoposide—urinary bladder cancer	0.000926	0.000985	CcSEcCtD
Flecainide—Haematuria—Methotrexate—urinary bladder cancer	0.000924	0.000983	CcSEcCtD
Flecainide—Dyspnoea—Etoposide—urinary bladder cancer	0.00092	0.000978	CcSEcCtD
Flecainide—Hyperglycaemia—Epirubicin—urinary bladder cancer	0.000917	0.000976	CcSEcCtD
Flecainide—Somnolence—Etoposide—urinary bladder cancer	0.000917	0.000975	CcSEcCtD
Flecainide—Angina pectoris—Doxorubicin—urinary bladder cancer	0.000917	0.000975	CcSEcCtD
Flecainide—Vomiting—Thiotepa—urinary bladder cancer	0.000913	0.000971	CcSEcCtD
Flecainide—Pneumonia—Epirubicin—urinary bladder cancer	0.000912	0.00097	CcSEcCtD
Flecainide—Rash—Thiotepa—urinary bladder cancer	0.000906	0.000963	CcSEcCtD
Flecainide—Dermatitis—Thiotepa—urinary bladder cancer	0.000905	0.000962	CcSEcCtD
Flecainide—Agranulocytosis—Methotrexate—urinary bladder cancer	0.000904	0.000962	CcSEcCtD
Flecainide—Headache—Thiotepa—urinary bladder cancer	0.0009	0.000957	CcSEcCtD
Flecainide—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP4B1—urinary bladder cancer	0.000898	0.015	CbGpPWpGaD
Flecainide—Decreased appetite—Etoposide—urinary bladder cancer	0.000897	0.000954	CcSEcCtD
Flecainide—Renal failure—Epirubicin—urinary bladder cancer	0.000891	0.000948	CcSEcCtD
Flecainide—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.000891	0.000947	CcSEcCtD
Flecainide—Body temperature increased—Cisplatin—urinary bladder cancer	0.00089	0.000947	CcSEcCtD
Flecainide—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP4B1—urinary bladder cancer	0.00089	0.0149	CbGpPWpGaD
Flecainide—Fatigue—Etoposide—urinary bladder cancer	0.00089	0.000946	CcSEcCtD
Flecainide—Neuropathy peripheral—Epirubicin—urinary bladder cancer	0.000889	0.000945	CcSEcCtD
Flecainide—CYP2D6—Oxidation by Cytochrome P450—CYP4B1—urinary bladder cancer	0.000886	0.0148	CbGpPWpGaD
Flecainide—Jaundice—Epirubicin—urinary bladder cancer	0.000884	0.00094	CcSEcCtD
Flecainide—Pain—Etoposide—urinary bladder cancer	0.000882	0.000938	CcSEcCtD
Flecainide—Constipation—Etoposide—urinary bladder cancer	0.000882	0.000938	CcSEcCtD
Flecainide—Dysuria—Doxorubicin—urinary bladder cancer	0.00088	0.000936	CcSEcCtD
Flecainide—CYP2C9—Oxidation by Cytochrome P450—CYP4B1—urinary bladder cancer	0.000878	0.0147	CbGpPWpGaD
Flecainide—Asthenia—Gemcitabine—urinary bladder cancer	0.000867	0.000922	CcSEcCtD
Flecainide—Haematuria—Epirubicin—urinary bladder cancer	0.000865	0.00092	CcSEcCtD
Flecainide—Photosensitivity reaction—Doxorubicin—urinary bladder cancer	0.000859	0.000914	CcSEcCtD
Flecainide—Pruritus—Gemcitabine—urinary bladder cancer	0.000855	0.000909	CcSEcCtD
Flecainide—Nausea—Thiotepa—urinary bladder cancer	0.000853	0.000907	CcSEcCtD
Flecainide—Feeling abnormal—Etoposide—urinary bladder cancer	0.00085	0.000904	CcSEcCtD
Flecainide—Hyperglycaemia—Doxorubicin—urinary bladder cancer	0.000849	0.000903	CcSEcCtD
Flecainide—Agranulocytosis—Epirubicin—urinary bladder cancer	0.000846	0.0009	CcSEcCtD
Flecainide—Pneumonia—Doxorubicin—urinary bladder cancer	0.000844	0.000898	CcSEcCtD
Flecainide—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000844	0.000897	CcSEcCtD
Flecainide—Pruritus—Fluorouracil—urinary bladder cancer	0.000841	0.000894	CcSEcCtD
Flecainide—Visual impairment—Methotrexate—urinary bladder cancer	0.000838	0.000892	CcSEcCtD
Flecainide—Bradycardia—Epirubicin—urinary bladder cancer	0.000829	0.000881	CcSEcCtD
Flecainide—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000827	0.000879	CcSEcCtD
Flecainide—Renal failure—Doxorubicin—urinary bladder cancer	0.000825	0.000877	CcSEcCtD
Flecainide—Neuropathy peripheral—Doxorubicin—urinary bladder cancer	0.000822	0.000875	CcSEcCtD
Flecainide—Urticaria—Etoposide—urinary bladder cancer	0.00082	0.000872	CcSEcCtD
Flecainide—Jaundice—Doxorubicin—urinary bladder cancer	0.000818	0.00087	CcSEcCtD
Flecainide—Body temperature increased—Etoposide—urinary bladder cancer	0.000816	0.000867	CcSEcCtD
Flecainide—Abdominal pain—Etoposide—urinary bladder cancer	0.000816	0.000867	CcSEcCtD
Flecainide—Eye disorder—Methotrexate—urinary bladder cancer	0.000813	0.000865	CcSEcCtD
Flecainide—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000813	0.000864	CcSEcCtD
Flecainide—Tinnitus—Methotrexate—urinary bladder cancer	0.000811	0.000863	CcSEcCtD
Flecainide—Hypoaesthesia—Epirubicin—urinary bladder cancer	0.00081	0.000861	CcSEcCtD
Flecainide—Asthenia—Cisplatin—urinary bladder cancer	0.000808	0.000859	CcSEcCtD
Flecainide—Haematuria—Doxorubicin—urinary bladder cancer	0.0008	0.000851	CcSEcCtD
Flecainide—Immune system disorder—Methotrexate—urinary bladder cancer	0.000786	0.000836	CcSEcCtD
Flecainide—Dizziness—Fluorouracil—urinary bladder cancer	0.000786	0.000835	CcSEcCtD
Flecainide—Visual impairment—Epirubicin—urinary bladder cancer	0.000785	0.000834	CcSEcCtD
Flecainide—Agranulocytosis—Doxorubicin—urinary bladder cancer	0.000783	0.000833	CcSEcCtD
Flecainide—Diarrhoea—Cisplatin—urinary bladder cancer	0.000771	0.00082	CcSEcCtD
Flecainide—Alopecia—Methotrexate—urinary bladder cancer	0.000769	0.000817	CcSEcCtD
Flecainide—Vomiting—Gemcitabine—urinary bladder cancer	0.000768	0.000817	CcSEcCtD
Flecainide—Bradycardia—Doxorubicin—urinary bladder cancer	0.000767	0.000816	CcSEcCtD
Flecainide—Rash—Gemcitabine—urinary bladder cancer	0.000762	0.00081	CcSEcCtD
Flecainide—Dermatitis—Gemcitabine—urinary bladder cancer	0.000761	0.000809	CcSEcCtD
Flecainide—Eye disorder—Epirubicin—urinary bladder cancer	0.000761	0.000809	CcSEcCtD
Flecainide—Tinnitus—Epirubicin—urinary bladder cancer	0.000759	0.000807	CcSEcCtD
Flecainide—Headache—Gemcitabine—urinary bladder cancer	0.000757	0.000805	CcSEcCtD
Flecainide—Flushing—Epirubicin—urinary bladder cancer	0.000756	0.000803	CcSEcCtD
Flecainide—Vomiting—Fluorouracil—urinary bladder cancer	0.000755	0.000803	CcSEcCtD
Flecainide—Hypoaesthesia—Doxorubicin—urinary bladder cancer	0.000749	0.000797	CcSEcCtD
Flecainide—Rash—Fluorouracil—urinary bladder cancer	0.000749	0.000797	CcSEcCtD
Flecainide—Dermatitis—Fluorouracil—urinary bladder cancer	0.000748	0.000796	CcSEcCtD
Flecainide—Headache—Fluorouracil—urinary bladder cancer	0.000744	0.000792	CcSEcCtD
Flecainide—Dysgeusia—Methotrexate—urinary bladder cancer	0.000742	0.000789	CcSEcCtD
Flecainide—Asthenia—Etoposide—urinary bladder cancer	0.00074	0.000787	CcSEcCtD
Flecainide—Immune system disorder—Epirubicin—urinary bladder cancer	0.000735	0.000782	CcSEcCtD
Flecainide—Pruritus—Etoposide—urinary bladder cancer	0.00073	0.000776	CcSEcCtD
Flecainide—CYP2D6—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.000728	0.0122	CbGpPWpGaD
Flecainide—Visual impairment—Doxorubicin—urinary bladder cancer	0.000726	0.000772	CcSEcCtD
Flecainide—CYP2C9—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.000721	0.0121	CbGpPWpGaD
Flecainide—Alopecia—Epirubicin—urinary bladder cancer	0.000719	0.000765	CcSEcCtD
Flecainide—CYP2C9—Constitutive Androstane Receptor Pathway—SMC1A—urinary bladder cancer	0.000719	0.012	CbGpPWpGaD
Flecainide—Nausea—Gemcitabine—urinary bladder cancer	0.000718	0.000763	CcSEcCtD
Flecainide—Vomiting—Cisplatin—urinary bladder cancer	0.000716	0.000762	CcSEcCtD
Flecainide—Vision blurred—Methotrexate—urinary bladder cancer	0.000714	0.000759	CcSEcCtD
Flecainide—SCN5A—Cardiac Progenitor Differentiation—IGF1—urinary bladder cancer	0.000711	0.0119	CbGpPWpGaD
Flecainide—Rash—Cisplatin—urinary bladder cancer	0.00071	0.000755	CcSEcCtD
Flecainide—Dermatitis—Cisplatin—urinary bladder cancer	0.000709	0.000754	CcSEcCtD
Flecainide—Diarrhoea—Etoposide—urinary bladder cancer	0.000706	0.000751	CcSEcCtD
Flecainide—Nausea—Fluorouracil—urinary bladder cancer	0.000706	0.00075	CcSEcCtD
Flecainide—Eye disorder—Doxorubicin—urinary bladder cancer	0.000704	0.000749	CcSEcCtD
Flecainide—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.000703	0.000747	CcSEcCtD
Flecainide—Tinnitus—Doxorubicin—urinary bladder cancer	0.000702	0.000747	CcSEcCtD
Flecainide—Flushing—Doxorubicin—urinary bladder cancer	0.000699	0.000743	CcSEcCtD
Flecainide—Flatulence—Epirubicin—urinary bladder cancer	0.000698	0.000743	CcSEcCtD
Flecainide—Tension—Epirubicin—urinary bladder cancer	0.000695	0.00074	CcSEcCtD
Flecainide—Dysgeusia—Epirubicin—urinary bladder cancer	0.000694	0.000738	CcSEcCtD
Flecainide—SCN4A—Developmental Biology—CNTN2—urinary bladder cancer	0.000691	0.0116	CbGpPWpGaD
Flecainide—Nervousness—Epirubicin—urinary bladder cancer	0.000688	0.000732	CcSEcCtD
Flecainide—Malaise—Methotrexate—urinary bladder cancer	0.000683	0.000726	CcSEcCtD
Flecainide—Dizziness—Etoposide—urinary bladder cancer	0.000682	0.000726	CcSEcCtD
Flecainide—Immune system disorder—Doxorubicin—urinary bladder cancer	0.00068	0.000724	CcSEcCtD
Flecainide—Vertigo—Methotrexate—urinary bladder cancer	0.00068	0.000724	CcSEcCtD
Flecainide—Leukopenia—Methotrexate—urinary bladder cancer	0.000678	0.000721	CcSEcCtD
Flecainide—Nausea—Cisplatin—urinary bladder cancer	0.000669	0.000711	CcSEcCtD
Flecainide—Vision blurred—Epirubicin—urinary bladder cancer	0.000668	0.00071	CcSEcCtD
Flecainide—Alopecia—Doxorubicin—urinary bladder cancer	0.000666	0.000708	CcSEcCtD
Flecainide—Cough—Methotrexate—urinary bladder cancer	0.000661	0.000703	CcSEcCtD
Flecainide—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.000658	0.000699	CcSEcCtD
Flecainide—SCN5A—Axon guidance—CNTN2—urinary bladder cancer	0.000657	0.011	CbGpPWpGaD
Flecainide—Convulsion—Methotrexate—urinary bladder cancer	0.000656	0.000698	CcSEcCtD
Flecainide—Vomiting—Etoposide—urinary bladder cancer	0.000656	0.000698	CcSEcCtD
Flecainide—Rash—Etoposide—urinary bladder cancer	0.000651	0.000692	CcSEcCtD
Flecainide—Dermatitis—Etoposide—urinary bladder cancer	0.00065	0.000691	CcSEcCtD
Flecainide—Headache—Etoposide—urinary bladder cancer	0.000646	0.000687	CcSEcCtD
Flecainide—Flatulence—Doxorubicin—urinary bladder cancer	0.000646	0.000687	CcSEcCtD
Flecainide—Chest pain—Methotrexate—urinary bladder cancer	0.000645	0.000686	CcSEcCtD
Flecainide—Myalgia—Methotrexate—urinary bladder cancer	0.000645	0.000686	CcSEcCtD
Flecainide—Arthralgia—Methotrexate—urinary bladder cancer	0.000645	0.000686	CcSEcCtD
Flecainide—Tension—Doxorubicin—urinary bladder cancer	0.000643	0.000684	CcSEcCtD
Flecainide—Dysgeusia—Doxorubicin—urinary bladder cancer	0.000642	0.000683	CcSEcCtD
Flecainide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.00064	0.000681	CcSEcCtD
Flecainide—Malaise—Epirubicin—urinary bladder cancer	0.000639	0.00068	CcSEcCtD
Flecainide—Discomfort—Methotrexate—urinary bladder cancer	0.000637	0.000677	CcSEcCtD
Flecainide—Nervousness—Doxorubicin—urinary bladder cancer	0.000637	0.000677	CcSEcCtD
Flecainide—Vertigo—Epirubicin—urinary bladder cancer	0.000637	0.000677	CcSEcCtD
Flecainide—Syncope—Epirubicin—urinary bladder cancer	0.000636	0.000676	CcSEcCtD
Flecainide—Leukopenia—Epirubicin—urinary bladder cancer	0.000634	0.000675	CcSEcCtD
Flecainide—Palpitations—Epirubicin—urinary bladder cancer	0.000626	0.000666	CcSEcCtD
Flecainide—Confusional state—Methotrexate—urinary bladder cancer	0.000623	0.000663	CcSEcCtD
Flecainide—Loss of consciousness—Epirubicin—urinary bladder cancer	0.000623	0.000662	CcSEcCtD
Flecainide—Cough—Epirubicin—urinary bladder cancer	0.000618	0.000658	CcSEcCtD
Flecainide—Vision blurred—Doxorubicin—urinary bladder cancer	0.000618	0.000657	CcSEcCtD
Flecainide—Convulsion—Epirubicin—urinary bladder cancer	0.000614	0.000653	CcSEcCtD
Flecainide—Nausea—Etoposide—urinary bladder cancer	0.000613	0.000652	CcSEcCtD
Flecainide—Hypertension—Epirubicin—urinary bladder cancer	0.000612	0.000651	CcSEcCtD
Flecainide—Ill-defined disorder—Doxorubicin—urinary bladder cancer	0.000608	0.000647	CcSEcCtD
Flecainide—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000606	0.000645	CcSEcCtD
Flecainide—Thrombocytopenia—Methotrexate—urinary bladder cancer	0.000605	0.000644	CcSEcCtD
Flecainide—Chest pain—Epirubicin—urinary bladder cancer	0.000603	0.000642	CcSEcCtD
Flecainide—Myalgia—Epirubicin—urinary bladder cancer	0.000603	0.000642	CcSEcCtD
Flecainide—Arthralgia—Epirubicin—urinary bladder cancer	0.000603	0.000642	CcSEcCtD
Flecainide—Anxiety—Epirubicin—urinary bladder cancer	0.000601	0.000639	CcSEcCtD
Flecainide—Skin disorder—Methotrexate—urinary bladder cancer	0.0006	0.000638	CcSEcCtD
Flecainide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000599	0.000637	CcSEcCtD
Flecainide—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.000597	0.000635	CcSEcCtD
Flecainide—Discomfort—Epirubicin—urinary bladder cancer	0.000596	0.000634	CcSEcCtD
Flecainide—Malaise—Doxorubicin—urinary bladder cancer	0.000591	0.000629	CcSEcCtD
Flecainide—Dry mouth—Epirubicin—urinary bladder cancer	0.00059	0.000628	CcSEcCtD
Flecainide—Vertigo—Doxorubicin—urinary bladder cancer	0.000589	0.000627	CcSEcCtD
Flecainide—Anorexia—Methotrexate—urinary bladder cancer	0.000589	0.000627	CcSEcCtD
Flecainide—Syncope—Doxorubicin—urinary bladder cancer	0.000588	0.000625	CcSEcCtD
Flecainide—Leukopenia—Doxorubicin—urinary bladder cancer	0.000587	0.000624	CcSEcCtD
Flecainide—Confusional state—Epirubicin—urinary bladder cancer	0.000583	0.00062	CcSEcCtD
Flecainide—Palpitations—Doxorubicin—urinary bladder cancer	0.000579	0.000616	CcSEcCtD
Flecainide—Oedema—Epirubicin—urinary bladder cancer	0.000578	0.000615	CcSEcCtD
Flecainide—Hypotension—Methotrexate—urinary bladder cancer	0.000578	0.000614	CcSEcCtD
Flecainide—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.000576	0.000613	CcSEcCtD
Flecainide—Cough—Doxorubicin—urinary bladder cancer	0.000572	0.000609	CcSEcCtD
Flecainide—SCN5A—SIDS Susceptibility Pathways—ESR2—urinary bladder cancer	0.000571	0.00957	CbGpPWpGaD
Flecainide—Shock—Epirubicin—urinary bladder cancer	0.000569	0.000605	CcSEcCtD
Flecainide—Convulsion—Doxorubicin—urinary bladder cancer	0.000568	0.000604	CcSEcCtD
Flecainide—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000567	0.000603	CcSEcCtD
Flecainide—Thrombocytopenia—Epirubicin—urinary bladder cancer	0.000566	0.000602	CcSEcCtD
Flecainide—Hypertension—Doxorubicin—urinary bladder cancer	0.000566	0.000602	CcSEcCtD
Flecainide—Tachycardia—Epirubicin—urinary bladder cancer	0.000564	0.0006	CcSEcCtD
Flecainide—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000563	0.000599	CcSEcCtD
Flecainide—Skin disorder—Epirubicin—urinary bladder cancer	0.000562	0.000597	CcSEcCtD
Flecainide—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.000559	0.000595	CcSEcCtD
Flecainide—Insomnia—Methotrexate—urinary bladder cancer	0.000559	0.000594	CcSEcCtD
Flecainide—Arthralgia—Doxorubicin—urinary bladder cancer	0.000558	0.000594	CcSEcCtD
Flecainide—Chest pain—Doxorubicin—urinary bladder cancer	0.000558	0.000594	CcSEcCtD
Flecainide—Myalgia—Doxorubicin—urinary bladder cancer	0.000558	0.000594	CcSEcCtD
Flecainide—Anxiety—Doxorubicin—urinary bladder cancer	0.000556	0.000592	CcSEcCtD
Flecainide—Paraesthesia—Methotrexate—urinary bladder cancer	0.000555	0.00059	CcSEcCtD
Flecainide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.000554	0.00059	CcSEcCtD
Flecainide—Discomfort—Doxorubicin—urinary bladder cancer	0.000552	0.000587	CcSEcCtD
Flecainide—Anorexia—Epirubicin—urinary bladder cancer	0.000551	0.000586	CcSEcCtD
Flecainide—Dyspnoea—Methotrexate—urinary bladder cancer	0.000551	0.000586	CcSEcCtD
Flecainide—Somnolence—Methotrexate—urinary bladder cancer	0.000549	0.000584	CcSEcCtD
Flecainide—CYP2C9—Arachidonic acid metabolism—HPGDS—urinary bladder cancer	0.000548	0.00918	CbGpPWpGaD
Flecainide—Dry mouth—Doxorubicin—urinary bladder cancer	0.000546	0.000581	CcSEcCtD
Flecainide—Dyspepsia—Methotrexate—urinary bladder cancer	0.000544	0.000579	CcSEcCtD
Flecainide—Hypotension—Epirubicin—urinary bladder cancer	0.00054	0.000575	CcSEcCtD
Flecainide—Confusional state—Doxorubicin—urinary bladder cancer	0.00054	0.000574	CcSEcCtD
Flecainide—Decreased appetite—Methotrexate—urinary bladder cancer	0.000537	0.000571	CcSEcCtD
Flecainide—Oedema—Doxorubicin—urinary bladder cancer	0.000535	0.000569	CcSEcCtD
Flecainide—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000534	0.000567	CcSEcCtD
Flecainide—Fatigue—Methotrexate—urinary bladder cancer	0.000533	0.000567	CcSEcCtD
Flecainide—Pain—Methotrexate—urinary bladder cancer	0.000529	0.000562	CcSEcCtD
Flecainide—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.000527	0.00056	CcSEcCtD
Flecainide—Shock—Doxorubicin—urinary bladder cancer	0.000527	0.00056	CcSEcCtD
Flecainide—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.000525	0.000558	CcSEcCtD
Flecainide—Thrombocytopenia—Doxorubicin—urinary bladder cancer	0.000524	0.000557	CcSEcCtD
Flecainide—Insomnia—Epirubicin—urinary bladder cancer	0.000523	0.000556	CcSEcCtD
Flecainide—Tachycardia—Doxorubicin—urinary bladder cancer	0.000522	0.000555	CcSEcCtD
Flecainide—Skin disorder—Doxorubicin—urinary bladder cancer	0.00052	0.000553	CcSEcCtD
Flecainide—Paraesthesia—Epirubicin—urinary bladder cancer	0.000519	0.000552	CcSEcCtD
Flecainide—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.000517	0.00055	CcSEcCtD
Flecainide—Dyspnoea—Epirubicin—urinary bladder cancer	0.000516	0.000548	CcSEcCtD
Flecainide—Somnolence—Epirubicin—urinary bladder cancer	0.000514	0.000547	CcSEcCtD
Flecainide—Anorexia—Doxorubicin—urinary bladder cancer	0.00051	0.000542	CcSEcCtD
Flecainide—Feeling abnormal—Methotrexate—urinary bladder cancer	0.000509	0.000542	CcSEcCtD
Flecainide—Dyspepsia—Epirubicin—urinary bladder cancer	0.000509	0.000541	CcSEcCtD
Flecainide—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000505	0.000537	CcSEcCtD
Flecainide—Decreased appetite—Epirubicin—urinary bladder cancer	0.000503	0.000535	CcSEcCtD
Flecainide—Hypotension—Doxorubicin—urinary bladder cancer	0.0005	0.000532	CcSEcCtD
Flecainide—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000499	0.000531	CcSEcCtD
Flecainide—Fatigue—Epirubicin—urinary bladder cancer	0.000499	0.00053	CcSEcCtD
Flecainide—CYP2D6—Biological oxidations—GSTZ1—urinary bladder cancer	0.000495	0.0083	CbGpPWpGaD
Flecainide—Pain—Epirubicin—urinary bladder cancer	0.000495	0.000526	CcSEcCtD
Flecainide—Constipation—Epirubicin—urinary bladder cancer	0.000495	0.000526	CcSEcCtD
Flecainide—Urticaria—Methotrexate—urinary bladder cancer	0.000491	0.000522	CcSEcCtD
Flecainide—CYP2C9—Biological oxidations—GSTZ1—urinary bladder cancer	0.000491	0.00822	CbGpPWpGaD
Flecainide—Abdominal pain—Methotrexate—urinary bladder cancer	0.000489	0.00052	CcSEcCtD
Flecainide—Body temperature increased—Methotrexate—urinary bladder cancer	0.000489	0.00052	CcSEcCtD
Flecainide—CYP2D6—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.000488	0.00818	CbGpPWpGaD
Flecainide—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000488	0.000519	CcSEcCtD
Flecainide—CYP2C9—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.000484	0.00811	CbGpPWpGaD
Flecainide—Insomnia—Doxorubicin—urinary bladder cancer	0.000484	0.000515	CcSEcCtD
Flecainide—Paraesthesia—Doxorubicin—urinary bladder cancer	0.000481	0.000511	CcSEcCtD
Flecainide—Dyspnoea—Doxorubicin—urinary bladder cancer	0.000477	0.000507	CcSEcCtD
Flecainide—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000477	0.000507	CcSEcCtD
Flecainide—Somnolence—Doxorubicin—urinary bladder cancer	0.000476	0.000506	CcSEcCtD
Flecainide—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000473	0.000503	CcSEcCtD
Flecainide—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000471	0.000501	CcSEcCtD
Flecainide—CYP2D6—Biological oxidations—GSTO2—urinary bladder cancer	0.000469	0.00786	CbGpPWpGaD
Flecainide—CYP2D6—Biological oxidations—NAT1—urinary bladder cancer	0.000469	0.00786	CbGpPWpGaD
Flecainide—SCN5A—Developmental Biology—CNTN2—urinary bladder cancer	0.000469	0.00785	CbGpPWpGaD
Flecainide—CYP2C9—Biological oxidations—GSTO2—urinary bladder cancer	0.000465	0.0078	CbGpPWpGaD
Flecainide—CYP2C9—Biological oxidations—NAT1—urinary bladder cancer	0.000465	0.0078	CbGpPWpGaD
Flecainide—Decreased appetite—Doxorubicin—urinary bladder cancer	0.000465	0.000495	CcSEcCtD
Flecainide—CYP2D6—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.000463	0.00776	CbGpPWpGaD
Flecainide—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000462	0.000491	CcSEcCtD
Flecainide—Fatigue—Doxorubicin—urinary bladder cancer	0.000461	0.000491	CcSEcCtD
Flecainide—Urticaria—Epirubicin—urinary bladder cancer	0.000459	0.000489	CcSEcCtD
Flecainide—CYP2C9—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.000459	0.00769	CbGpPWpGaD
Flecainide—Constipation—Doxorubicin—urinary bladder cancer	0.000458	0.000487	CcSEcCtD
Flecainide—Pain—Doxorubicin—urinary bladder cancer	0.000458	0.000487	CcSEcCtD
Flecainide—Abdominal pain—Epirubicin—urinary bladder cancer	0.000457	0.000486	CcSEcCtD
Flecainide—Body temperature increased—Epirubicin—urinary bladder cancer	0.000457	0.000486	CcSEcCtD
Flecainide—Asthenia—Methotrexate—urinary bladder cancer	0.000443	0.000472	CcSEcCtD
Flecainide—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000441	0.000469	CcSEcCtD
Flecainide—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000438	0.000465	CcSEcCtD
Flecainide—SCN4A—L1CAM interactions—SRC—urinary bladder cancer	0.000437	0.00733	CbGpPWpGaD
Flecainide—Pruritus—Methotrexate—urinary bladder cancer	0.000437	0.000465	CcSEcCtD
Flecainide—CYP2D6—Biological oxidations—UGT2B7—urinary bladder cancer	0.000429	0.00719	CbGpPWpGaD
Flecainide—CYP2C9—Biological oxidations—UGT2B7—urinary bladder cancer	0.000426	0.00713	CbGpPWpGaD
Flecainide—Urticaria—Doxorubicin—urinary bladder cancer	0.000425	0.000452	CcSEcCtD
Flecainide—CYP2D6—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.000423	0.00709	CbGpPWpGaD
Flecainide—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000423	0.00045	CcSEcCtD
Flecainide—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000423	0.00045	CcSEcCtD
Flecainide—Diarrhoea—Methotrexate—urinary bladder cancer	0.000423	0.00045	CcSEcCtD
Flecainide—CYP2C9—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.00042	0.00703	CbGpPWpGaD
Flecainide—Asthenia—Epirubicin—urinary bladder cancer	0.000415	0.000441	CcSEcCtD
Flecainide—Pruritus—Epirubicin—urinary bladder cancer	0.000409	0.000435	CcSEcCtD
Flecainide—Dizziness—Methotrexate—urinary bladder cancer	0.000409	0.000435	CcSEcCtD
Flecainide—Diarrhoea—Epirubicin—urinary bladder cancer	0.000396	0.000421	CcSEcCtD
Flecainide—Vomiting—Methotrexate—urinary bladder cancer	0.000393	0.000418	CcSEcCtD
Flecainide—Rash—Methotrexate—urinary bladder cancer	0.00039	0.000414	CcSEcCtD
Flecainide—Dermatitis—Methotrexate—urinary bladder cancer	0.000389	0.000414	CcSEcCtD
Flecainide—Headache—Methotrexate—urinary bladder cancer	0.000387	0.000412	CcSEcCtD
Flecainide—CYP2D6—Biological oxidations—CYP4B1—urinary bladder cancer	0.000387	0.00648	CbGpPWpGaD
Flecainide—Asthenia—Doxorubicin—urinary bladder cancer	0.000384	0.000408	CcSEcCtD
Flecainide—SCN4A—L1CAM interactions—EGFR—urinary bladder cancer	0.000383	0.00642	CbGpPWpGaD
Flecainide—CYP2C9—Biological oxidations—CYP4B1—urinary bladder cancer	0.000383	0.00642	CbGpPWpGaD
Flecainide—Dizziness—Epirubicin—urinary bladder cancer	0.000382	0.000407	CcSEcCtD
Flecainide—CYP2D6—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000381	0.00639	CbGpPWpGaD
Flecainide—Pruritus—Doxorubicin—urinary bladder cancer	0.000379	0.000403	CcSEcCtD
Flecainide—CYP2C9—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000378	0.00633	CbGpPWpGaD
Flecainide—Vomiting—Epirubicin—urinary bladder cancer	0.000368	0.000391	CcSEcCtD
Flecainide—Nausea—Methotrexate—urinary bladder cancer	0.000367	0.00039	CcSEcCtD
Flecainide—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000366	0.000389	CcSEcCtD
Flecainide—Rash—Epirubicin—urinary bladder cancer	0.000365	0.000388	CcSEcCtD
Flecainide—Dermatitis—Epirubicin—urinary bladder cancer	0.000364	0.000387	CcSEcCtD
Flecainide—Headache—Epirubicin—urinary bladder cancer	0.000362	0.000385	CcSEcCtD
Flecainide—Dizziness—Doxorubicin—urinary bladder cancer	0.000354	0.000376	CcSEcCtD
Flecainide—Nausea—Epirubicin—urinary bladder cancer	0.000344	0.000365	CcSEcCtD
Flecainide—Vomiting—Doxorubicin—urinary bladder cancer	0.00034	0.000362	CcSEcCtD
Flecainide—Rash—Doxorubicin—urinary bladder cancer	0.000337	0.000359	CcSEcCtD
Flecainide—Dermatitis—Doxorubicin—urinary bladder cancer	0.000337	0.000359	CcSEcCtD
Flecainide—Headache—Doxorubicin—urinary bladder cancer	0.000335	0.000357	CcSEcCtD
Flecainide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	0.00033	0.00553	CbGpPWpGaD
Flecainide—CYP2C9—Arachidonic acid metabolism—GPX1—urinary bladder cancer	0.000324	0.00543	CbGpPWpGaD
Flecainide—Nausea—Doxorubicin—urinary bladder cancer	0.000318	0.000338	CcSEcCtD
Flecainide—SCN5A—SIDS Susceptibility Pathways—CREBBP—urinary bladder cancer	0.000304	0.00509	CbGpPWpGaD
Flecainide—SCN5A—L1CAM interactions—SRC—urinary bladder cancer	0.000297	0.00497	CbGpPWpGaD
Flecainide—SCN5A—L1CAM interactions—EGFR—urinary bladder cancer	0.00026	0.00435	CbGpPWpGaD
Flecainide—SCN4A—Developmental Biology—NCOR1—urinary bladder cancer	0.000259	0.00433	CbGpPWpGaD
Flecainide—CYP2D6—Biological oxidations—NAT2—urinary bladder cancer	0.000257	0.00431	CbGpPWpGaD
Flecainide—CYP2C9—Biological oxidations—NAT2—urinary bladder cancer	0.000255	0.00427	CbGpPWpGaD
Flecainide—CYP2D6—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000254	0.00425	CbGpPWpGaD
Flecainide—CYP2C9—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000251	0.00421	CbGpPWpGaD
Flecainide—SCN5A—SIDS Susceptibility Pathways—CXCL8—urinary bladder cancer	0.000241	0.00404	CbGpPWpGaD
Flecainide—SCN4A—Axon guidance—RHOA—urinary bladder cancer	0.000226	0.00378	CbGpPWpGaD
Flecainide—SCN4A—Axon guidance—ERBB2—urinary bladder cancer	0.000209	0.0035	CbGpPWpGaD
Flecainide—SCN5A—SIDS Susceptibility Pathways—EP300—urinary bladder cancer	0.000207	0.00346	CbGpPWpGaD
Flecainide—CYP2D6—Biological oxidations—HPGDS—urinary bladder cancer	0.000206	0.00344	CbGpPWpGaD
Flecainide—SCN4A—Developmental Biology—CDK4—urinary bladder cancer	0.000204	0.00342	CbGpPWpGaD
Flecainide—CYP2C9—Biological oxidations—HPGDS—urinary bladder cancer	0.000204	0.00342	CbGpPWpGaD
Flecainide—CYP2D6—Biological oxidations—GSTT1—urinary bladder cancer	0.000199	0.00334	CbGpPWpGaD
Flecainide—CYP2C9—Biological oxidations—GSTT1—urinary bladder cancer	0.000198	0.00331	CbGpPWpGaD
Flecainide—CYP2C9—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	0.000191	0.0032	CbGpPWpGaD
Flecainide—SCN4A—Developmental Biology—PPARG—urinary bladder cancer	0.000185	0.00311	CbGpPWpGaD
Flecainide—SCN4A—Axon guidance—MMP9—urinary bladder cancer	0.000179	0.003	CbGpPWpGaD
Flecainide—SCN4A—Developmental Biology—CREBBP—urinary bladder cancer	0.000178	0.00298	CbGpPWpGaD
Flecainide—SCN5A—Developmental Biology—NCOR1—urinary bladder cancer	0.000175	0.00294	CbGpPWpGaD
Flecainide—SCN5A—SIDS Susceptibility Pathways—TNF—urinary bladder cancer	0.000168	0.00281	CbGpPWpGaD
Flecainide—SCN4A—Axon guidance—SRC—urinary bladder cancer	0.000165	0.00277	CbGpPWpGaD
Flecainide—SCN4A—Developmental Biology—RHOA—urinary bladder cancer	0.000161	0.0027	CbGpPWpGaD
Flecainide—SCN5A—Axon guidance—RHOA—urinary bladder cancer	0.000153	0.00256	CbGpPWpGaD
Flecainide—SCN4A—Developmental Biology—ERBB2—urinary bladder cancer	0.000149	0.0025	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.000147	0.00247	CbGpPWpGaD
Flecainide—SCN4A—Axon guidance—EGFR—urinary bladder cancer	0.000145	0.00243	CbGpPWpGaD
Flecainide—SCN5A—Axon guidance—ERBB2—urinary bladder cancer	0.000142	0.00237	CbGpPWpGaD
Flecainide—SCN5A—Developmental Biology—CDK4—urinary bladder cancer	0.000138	0.00232	CbGpPWpGaD
Flecainide—CYP2D6—Biological oxidations—GSTP1—urinary bladder cancer	0.000138	0.00232	CbGpPWpGaD
Flecainide—CYP2C9—Biological oxidations—GSTP1—urinary bladder cancer	0.000137	0.0023	CbGpPWpGaD
Flecainide—SCN4A—Axon guidance—KRAS—urinary bladder cancer	0.000137	0.00229	CbGpPWpGaD
Flecainide—CYP2D6—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000136	0.00228	CbGpPWpGaD
Flecainide—CYP2C9—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000135	0.00226	CbGpPWpGaD
Flecainide—SCN4A—Developmental Biology—MMP9—urinary bladder cancer	0.000128	0.00214	CbGpPWpGaD
Flecainide—CYP2D6—Biological oxidations—GSTM1—urinary bladder cancer	0.000127	0.00213	CbGpPWpGaD
Flecainide—CYP2C9—Biological oxidations—GSTM1—urinary bladder cancer	0.000126	0.00211	CbGpPWpGaD
Flecainide—SCN5A—Developmental Biology—PPARG—urinary bladder cancer	0.000126	0.00211	CbGpPWpGaD
Flecainide—CYP2D6—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000125	0.0021	CbGpPWpGaD
Flecainide—CYP2C9—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000124	0.00208	CbGpPWpGaD
Flecainide—SCN5A—Axon guidance—MMP9—urinary bladder cancer	0.000122	0.00204	CbGpPWpGaD
Flecainide—SCN4A—Developmental Biology—EP300—urinary bladder cancer	0.000121	0.00203	CbGpPWpGaD
Flecainide—SCN5A—Developmental Biology—CREBBP—urinary bladder cancer	0.000121	0.00202	CbGpPWpGaD
Flecainide—SCN4A—Developmental Biology—SRC—urinary bladder cancer	0.000118	0.00198	CbGpPWpGaD
Flecainide—SCN4A—Axon guidance—HRAS—urinary bladder cancer	0.000116	0.00195	CbGpPWpGaD
Flecainide—SCN5A—Axon guidance—SRC—urinary bladder cancer	0.000112	0.00188	CbGpPWpGaD
Flecainide—SCN5A—Developmental Biology—RHOA—urinary bladder cancer	0.000109	0.00183	CbGpPWpGaD
Flecainide—SCN4A—Developmental Biology—EGFR—urinary bladder cancer	0.000103	0.00173	CbGpPWpGaD
Flecainide—SCN5A—Developmental Biology—ERBB2—urinary bladder cancer	0.000101	0.00169	CbGpPWpGaD
Flecainide—SCN4A—Developmental Biology—TNF—urinary bladder cancer	9.85e-05	0.00165	CbGpPWpGaD
Flecainide—SCN5A—Axon guidance—EGFR—urinary bladder cancer	9.82e-05	0.00165	CbGpPWpGaD
Flecainide—SCN4A—Developmental Biology—KRAS—urinary bladder cancer	9.77e-05	0.00164	CbGpPWpGaD
Flecainide—SCN5A—Axon guidance—KRAS—urinary bladder cancer	9.28e-05	0.00155	CbGpPWpGaD
Flecainide—SCN5A—Developmental Biology—MMP9—urinary bladder cancer	8.67e-05	0.00145	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—GSTZ1—urinary bladder cancer	8.47e-05	0.00142	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—GSTZ1—urinary bladder cancer	8.4e-05	0.00141	CbGpPWpGaD
Flecainide—SCN4A—Developmental Biology—HRAS—urinary bladder cancer	8.3e-05	0.00139	CbGpPWpGaD
Flecainide—SCN5A—Developmental Biology—EP300—urinary bladder cancer	8.22e-05	0.00138	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—GSTO2—urinary bladder cancer	8.03e-05	0.00134	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—NAT1—urinary bladder cancer	8.03e-05	0.00134	CbGpPWpGaD
Flecainide—SCN5A—Developmental Biology—SRC—urinary bladder cancer	8e-05	0.00134	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—GSTO2—urinary bladder cancer	7.96e-05	0.00133	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—NAT1—urinary bladder cancer	7.96e-05	0.00133	CbGpPWpGaD
Flecainide—SCN5A—Axon guidance—HRAS—urinary bladder cancer	7.89e-05	0.00132	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	7.83e-05	0.00131	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—UGT2B7—urinary bladder cancer	7.34e-05	0.00123	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—UGT2B7—urinary bladder cancer	7.28e-05	0.00122	CbGpPWpGaD
Flecainide—SCN5A—Developmental Biology—EGFR—urinary bladder cancer	7.01e-05	0.00117	CbGpPWpGaD
Flecainide—SCN5A—Developmental Biology—TNF—urinary bladder cancer	6.68e-05	0.00112	CbGpPWpGaD
Flecainide—SCN5A—Developmental Biology—KRAS—urinary bladder cancer	6.62e-05	0.00111	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—CYP4B1—urinary bladder cancer	6.61e-05	0.00111	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—CYP4B1—urinary bladder cancer	6.55e-05	0.0011	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—SLC19A1—urinary bladder cancer	6.24e-05	0.00105	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—SLC19A1—urinary bladder cancer	6.19e-05	0.00104	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—PRSS3—urinary bladder cancer	6.08e-05	0.00102	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—PRSS3—urinary bladder cancer	6.03e-05	0.00101	CbGpPWpGaD
Flecainide—SCN5A—Developmental Biology—HRAS—urinary bladder cancer	5.63e-05	0.000943	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—TYMP—urinary bladder cancer	4.86e-05	0.000815	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	4.84e-05	0.00081	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—TYMP—urinary bladder cancer	4.82e-05	0.000808	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	4.63e-05	0.000776	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—NAT2—urinary bladder cancer	4.4e-05	0.000737	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—NAT2—urinary bladder cancer	4.36e-05	0.000731	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—RRM2—urinary bladder cancer	3.8e-05	0.000636	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—RRM2—urinary bladder cancer	3.76e-05	0.000631	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—ENO2—urinary bladder cancer	3.52e-05	0.000589	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—HPGDS—urinary bladder cancer	3.52e-05	0.000589	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—HPGDS—urinary bladder cancer	3.49e-05	0.000584	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—ENO2—urinary bladder cancer	3.49e-05	0.000584	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	3.47e-05	0.000581	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—GSTT1—urinary bladder cancer	3.41e-05	0.000571	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—GSTT1—urinary bladder cancer	3.38e-05	0.000566	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	3.33e-05	0.000558	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—NQO1—urinary bladder cancer	2.83e-05	0.000475	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—NQO1—urinary bladder cancer	2.81e-05	0.000471	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	2.73e-05	0.000457	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	2.38e-05	0.000398	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—GSTP1—urinary bladder cancer	2.36e-05	0.000396	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—GSTP1—urinary bladder cancer	2.34e-05	0.000393	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	2.27e-05	0.00038	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—TYMS—urinary bladder cancer	2.2e-05	0.000368	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—TYMS—urinary bladder cancer	2.18e-05	0.000365	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—NCOR1—urinary bladder cancer	2.17e-05	0.000364	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—GSTM1—urinary bladder cancer	2.17e-05	0.000364	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—NCOR1—urinary bladder cancer	2.15e-05	0.000361	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—GSTM1—urinary bladder cancer	2.15e-05	0.000361	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—GPX1—urinary bladder cancer	2.08e-05	0.000349	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—GPX1—urinary bladder cancer	2.06e-05	0.000346	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—ERCC2—urinary bladder cancer	2.04e-05	0.000342	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—ERCC2—urinary bladder cancer	2.02e-05	0.000339	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—MTHFR—urinary bladder cancer	1.92e-05	0.000322	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—MTHFR—urinary bladder cancer	1.9e-05	0.000319	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—PPARG—urinary bladder cancer	1.56e-05	0.000261	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—PPARG—urinary bladder cancer	1.54e-05	0.000259	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—CREBBP—urinary bladder cancer	1.5e-05	0.000251	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—CREBBP—urinary bladder cancer	1.48e-05	0.000248	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—PTGS2—urinary bladder cancer	1.22e-05	0.000205	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—PTGS2—urinary bladder cancer	1.21e-05	0.000203	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—PTEN—urinary bladder cancer	1.07e-05	0.000179	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—PTEN—urinary bladder cancer	1.06e-05	0.000177	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—EP300—urinary bladder cancer	1.02e-05	0.000171	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—EP300—urinary bladder cancer	1.01e-05	0.000169	CbGpPWpGaD
